Save Geography at the University of Leicester

Ayeisha Thomas-Smith is joined by Keir Milburn and Frances Northrop

As scholars within and beyond academia, we write in solidarity with academic freedom of expression with our colleague, Dr. Farhana Sultana, an internationally recognized scholar and tenured Full Profe...

Chancellor says she is focused on priorities for British people in pre-budget speech laying ground for expected tax rises

On Wednesday 26th November, we will be joined for a guest lecture by Prof John Tomaney from UCL.

King’s brother will surrender lease and become known as Andrew Mountbatten Windsor, Buckingham Palace says

An extraordinary meeting of the council, called to discuss a motion to cut all ties with ‘Israel’s genocide’, led to an ‘inflamed’ debate

As we enter Urban October we are pleased to share a series of events, gatherings and activities organised by the Urban Institute to celebrate ten years of urban research at the University of Sheffield...

Israeli police make nine arrests, citing ‘disorderly conduct, riots, injured police officers’ and infrastructure damage

Cycling x Solidarity's latest mutual aid effort takes cyclists on group rides through Pilsen and other neighborhoods to buy out tamale vendors so they can stay home as ICE agents swarm the city. They ...

YouTube video by Bold Politics with Zack Polanski

The automation of death has been a goal of the US military since 2004. The aim has been to progress from ‘man-in-the-loop’ technology, where a human decides what the technology does, to ‘man-on-the-lo...

Recent advancements in immunotherapy, particularly Chimeric antigen receptor (CAR)-T cell therapy and cancer vaccines, have significantly transformed the treatment landscape for leukemia. CAR-T cell therapy, initially promising in hematologic cancers, faces notable obstacles in solid tumors due to the complex and immunosuppressive tumor microenvironment. Challenges include the heterogeneous immune profiles of tumors, variability in antigen expression, difficulties in therapeutic delivery, T cell exhaustion, and reduced cytotoxic activity at the tumor site. Additionally, the physical barriers within tumors and the immunological camouflage used by cancer cells further complicate treatment efficacy. To overcome these hurdles, ongoing research explores the synergistic potential of combining CAR-T cell therapy with cancer vaccines and other therapeutic strategies such as checkpoint inhibitors and cytokine therapy. This review describes the various immunotherapeutic approaches targeting leukemia, emphasizing the roles and interplay of cancer vaccines and CAR-T cell therapy. In addition, by discussing how these therapies individually and collectively contribute to tumor regression, this article aims to highlight innovative treatment paradigms that could enhance clinical outcomes for leukemia patients. This integrative approach promises to pave the way for more effective and durable treatment strategies in the oncology field. These combined immunotherapeutic strategies hold great promise for achieving more complete and lasting remissions in leukemia patients. Future research should prioritize optimizing treatment sequencing, personalizing therapeutic combinations based on individual patient and tumor characteristics, and developing novel strategies to enhance T cell persistence and function within the tumor microenvironment. Ultimately, these efforts will advance the development of more effective and less toxic immunotherapeutic interventions, offering new hope for patients battling this challenging disease. Graphical Abstract

A message of neighbourly solidarity is thriving in Birmingham against a backdrop of racist intimidation